Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Vanda Pharmaceuticals' Shares Are Soaring 10% Today

By Todd Campbell - Sep 26, 2018 at 2:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is being added to a major market index.

What happened

After it was announced yesterday that the stock would be added to the S&P 600 index, shares in Vanda Pharmaceuticals ( VNDA -2.11% ) jumped on Wednesday and were up 10% at 2 p.m. EDT. 

So what

Vanda Pharmaceuticals will replace Inogen in the S&P Small Cap 600 Index prior to the market open on Oct. 1, so the rally in its shares is likely due to traders moving into the stock ahead of demand from index mutual funds and exchange-traded funds that track that index.

A passenger plane soaring into the sky.


The addition of Vanda Pharmaceuticals is a reflection of the progress it's made, including the successful launch of Hetlioz, a treatment for non-24, a sleep-wake disorder that affects about 80,000 Americans. In the second quarter, Hetlioz sales totaled $28 million, up 10% from Q1 2018 and 25% higher than in Q2 2017.

When combined with revenue from Fanapt, a schizophrenia drug, Vanda Pharmaceuticals' sales were $47.4 million last quarter, up 13% from $42.1 million in the prior-year period. Thanks to a tight lid on expenses, the revenue growth allowed the company to deliver non-GAAP net income of $7.7 million, or $0.15 per share, in the quarter. 

Now what

Management's guiding for full-year product sales of between $180 million and $200 million in 2018, and it's targeting cash of $225 million to $235 million at year's end.

That should give it plenty of financial flexibility to execute its current R&D plans and potentially launch Hetlioz as a treatment for jet leg. The company has already announced positive phase 3 data in jet lag, and an FDA filing is expected soon. If the FDA OKs expanding Hetlioz's label, then its sales could enjoy additional tailwinds beginning as early as 2019. 

Further back in its pipeline, data for Hetlioz in Smith-Magenis syndrome (a developmental disorder that includes disturbed sleep patterns) and data from a trial evaluating another drug, tradipitant, in gastroparesis (delayed gastric emptying) are expected before the end of 2018, and a phase 3 study of tradipitant for chronic itch in eczema patients is on tap.

Since Hetlioz's sales growth has allowed it to turn the corner to profitability and the company has irons in the fire that could further revenue growth in the future, this is an intriguing stock to consider owning in risk-tolerant, small-market-cap portfolios.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vanda Pharmaceuticals Inc. Stock Quote
Vanda Pharmaceuticals Inc.
$16.22 (-2.11%) $0.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.